Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-12-13 DOI:10.1016/j.medj.2024.10.018

Kriti Mittal, Monika Joshi

引用次数: 0

Abstract

The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.¹ In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.

查看原文本刊更多论文

尿路上皮癌围手术期免疫疗法：AMBASSADOR 为我们指明了前进的道路。

AMBASSADOR 试验显示，与观察结果相比，辅助使用 pembrolizumab 治疗高危肌层浸润性尿路上皮癌患者的无病生存率有所提高1。在本视点中，我们将结合 CheckMate-274 和最近发表的 NIAGARA 试验的前期数据，讨论这些发现的临床意义，展望围手术期免疫疗法的未来之路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.